1. Home
  2. LEGT vs ALT Comparison

LEGT vs ALT Comparison

Compare LEGT & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGT
  • ALT
  • Stock Information
  • Founded
  • LEGT 2023
  • ALT 1997
  • Country
  • LEGT United States
  • ALT United States
  • Employees
  • LEGT N/A
  • ALT N/A
  • Industry
  • LEGT
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • LEGT
  • ALT Health Care
  • Exchange
  • LEGT Nasdaq
  • ALT Nasdaq
  • Market Cap
  • LEGT 276.8M
  • ALT 327.4M
  • IPO Year
  • LEGT 2024
  • ALT N/A
  • Fundamental
  • Price
  • LEGT $10.77
  • ALT $3.59
  • Analyst Decision
  • LEGT
  • ALT Strong Buy
  • Analyst Count
  • LEGT 0
  • ALT 6
  • Target Price
  • LEGT N/A
  • ALT $17.40
  • AVG Volume (30 Days)
  • LEGT 21.9K
  • ALT 2.5M
  • Earning Date
  • LEGT 01-01-0001
  • ALT 11-11-2025
  • Dividend Yield
  • LEGT N/A
  • ALT N/A
  • EPS Growth
  • LEGT N/A
  • ALT N/A
  • EPS
  • LEGT 0.35
  • ALT N/A
  • Revenue
  • LEGT N/A
  • ALT $20,000.00
  • Revenue This Year
  • LEGT N/A
  • ALT N/A
  • Revenue Next Year
  • LEGT N/A
  • ALT $761,880.20
  • P/E Ratio
  • LEGT $30.68
  • ALT N/A
  • Revenue Growth
  • LEGT N/A
  • ALT N/A
  • 52 Week Low
  • LEGT $10.18
  • ALT $2.90
  • 52 Week High
  • LEGT $10.86
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • LEGT 61.22
  • ALT 44.54
  • Support Level
  • LEGT $10.72
  • ALT $3.60
  • Resistance Level
  • LEGT $10.74
  • ALT $3.82
  • Average True Range (ATR)
  • LEGT 0.01
  • ALT 0.17
  • MACD
  • LEGT 0.00
  • ALT 0.02
  • Stochastic Oscillator
  • LEGT 83.33
  • ALT 47.52

About LEGT Legato Merger Corp. III

Legato Merger Corp III is a blank check company.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: